<DOC>
	<DOCNO>NCT00986635</DOCNO>
	<brief_summary>Rivaroxaban represent new class anticoagulation agent . As oral direct factor Xa inhibitor effective prevent venous thromboembolism patient undergo elective orthopaedic surgery . This ex vivo study undertaken investigate ex-vivo effect Xarelto® different coagulation parameter .</brief_summary>
	<brief_title>Effect Rivaroxaban Coagulation Parameters- ex Vivo Study</brief_title>
	<detailed_description>To validate effect Rivaroxaban coagulation parameter plasma sample patient hip knee replacement surgery treat Rivaroxaban 10 mg/d investigate . Plasma sample obtain blood collection , 2 hour 12 hour Rivaroxaban dose steady state ( 3rd - 5th day ) . Several technique , include clot-based test , chromogenic assay ELISA´s use coagulation assay coagulation laboratory Frankfurt/Main . The influence Rivaroxaban different coagulation assay investigate coagulation laboratory .</detailed_description>
	<mesh_term>Antithrombins</mesh_term>
	<criteria>patient hip knee replacement surgery treat Rivaroxaban 10 mg/d must able accept blood sample</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Activated partial thromboplastin time</keyword>
	<keyword>Thrombin clotting Time</keyword>
	<keyword>Anti-Xa-activity</keyword>
	<keyword>Factor X-activity</keyword>
	<keyword>Factor XIII-activity</keyword>
	<keyword>Antithrombin ( base factor II )</keyword>
	<keyword>Antithrombin ( base factor X &lt; 9</keyword>
</DOC>